Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C17H18FN3O3.2ClH.3H2O |
| Molecular Weight | 789.651 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.Cl.Cl.OC(=O)C1=CN(C2CC2)C3=C(C=C(F)C(=C3)N4CCNCC4)C1=O.OC(=O)C5=CN(C6CC6)C7=C(C=C(F)C(=C7)N8CCNCC8)C5=O
InChI
InChIKey=SMFVXHJJUFAKBS-UHFFFAOYSA-N
InChI=1S/2C17H18FN3O3.2ClH.3H2O/c2*18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24;;;;;/h2*7-10,19H,1-6H2,(H,23,24);2*1H;3*1H2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C17H18FN3O3 |
| Molecular Weight | 331.3415 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/ciprofloxacin.html | https://clinicaltrials.gov/ct2/show/NCT02598362 | https://www.ncbi.nlm.nih.gov/pubmed/25951434
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/ciprofloxacin.html | https://clinicaltrials.gov/ct2/show/NCT02598362 | https://www.ncbi.nlm.nih.gov/pubmed/25951434
Ciprofloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid) is the synthetic antimicrobial agent for oral or intravenous administration. Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents. The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination. Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid. In the United States, ciprofloxacin is pregnancy category C. This category includes drugs for which no adequate and well-controlled studies in human pregnancy exist, and for which animal studies have suggested the potential for harm to the fetus, but potential benefits may warrant use of the drug in pregnant women despite potential risks. Fluoroquinolones have been reported as present in a mother's milk and thus passed on to the nursing child. Oral and intravenous ciprofloxacin is approved by the FDA for use in children for only two indications due to the risk of permanent injury to the musculoskeletal system: Inhalational anthrax (postexposure) and Complicated urinary tract infections and pyelonephritis due to Escherichia coli.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3329081 |
|||
Target ID: CHEMBL2311224 |
150.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | CIPRO Approved UseCiprofloxacin Tablets, USP are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin susceptible Staphylococcus aureus, methicillin susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei † when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. Pediatric patients (1 to 17 years of age)Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS, PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric PatientsInhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION ). †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Tablets and other antibacterial drugs, Ciprofloxacin Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1990 |
|||
| Curative | CIPRO Approved UseCiprofloxacin Tablets, USP are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin susceptible Staphylococcus aureus, methicillin susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei † when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. Pediatric patients (1 to 17 years of age)Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS, PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric PatientsInhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION ). †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Tablets and other antibacterial drugs, Ciprofloxacin Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1990 |
|||
| Curative | CIPRO Approved UseCiprofloxacin Tablets, USP are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin susceptible Staphylococcus aureus, methicillin susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei † when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. Pediatric patients (1 to 17 years of age)Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS, PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric PatientsInhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION ). †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Tablets and other antibacterial drugs, Ciprofloxacin Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1990 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.97 μg/mL |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.56 μg/mL |
400 mg 2 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
3.59 μg/mL |
750 mg 2 times / day steady-state, oral dose: 750 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.07 μg/mL |
400 mg 3 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
1.2 μg/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
2.4 μg/mL |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.3 μg/mL |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
5.4 μg/mL |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13.7 μg × h/mL |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
12.7 μg × h/mL |
400 mg 2 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
31.6 μg × h/mL |
750 mg 2 times / day steady-state, oral dose: 750 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
32.9 μg × h/mL |
400 mg 3 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.8 μg × h/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
11.6 μg × h/mL |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
20.2 μg × h/mL |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
30.8 μg × h/mL |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4 h |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4 h |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4 h |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4 h |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4 h |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30% |
500 mg 2 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CIPROFLOXACIN serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 mg/kg 2 times / day steady, oral Recommended Dose: 15 mg/kg, 2 times / day Route: oral Route: steady Dose: 15 mg/kg, 2 times / day Sources: |
unhealthy, 1 - 17 years Health Status: unhealthy Age Group: 1 - 17 years Sex: unknown Sources: |
Disc. AE: Reaction gastrointestinal... Other AEs: Musculoskeletal disorder NOS... AEs leading to discontinuation/dose reduction: Reaction gastrointestinal (3%) Other AEs:Musculoskeletal disorder NOS (9.3%) Sources: |
7.5 g single, oral Overdose |
unhealthy, 15 years |
Disc. AE: Renal tubular necrosis acute... AEs leading to discontinuation/dose reduction: Renal tubular necrosis acute (1 patient) Sources: |
12 g single, oral Overdose |
healthy, 16 years |
Disc. AE: Pain epigastric... AEs leading to discontinuation/dose reduction: Pain epigastric (1 patient) Sources: |
20 mg/kg single, oral Recommended Dose: 20 mg/kg Route: oral Route: single Dose: 20 mg/kg Sources: |
unhealthy, 2-15 years Health Status: unhealthy Age Group: 2-15 years Sex: M+F Sources: |
Other AEs: Vomited... |
28 g single, oral Overdose |
healthy, 29 years |
Disc. AE: Acute renal failure... AEs leading to discontinuation/dose reduction: Acute renal failure (1 patient) Sources: |
750 mg 2 times / day steady, oral Highest studied dose Dose: 750 mg, 2 times / day Route: oral Route: steady Dose: 750 mg, 2 times / day Sources: |
unhealthy, > 70 years Health Status: unhealthy Age Group: > 70 years Sex: M+F Sources: |
Disc. AE: Acute renal failure... AEs leading to discontinuation/dose reduction: Acute renal failure (2 patients) Sources: |
3 g single, oral Overdose |
healthy, adult |
Disc. AE: Nausea and vomiting... AEs leading to discontinuation/dose reduction: Nausea and vomiting (2 patients) Sources: |
228 mg 2 times / day steady, intravenous Recommended Dose: 228 mg, 2 times / day Route: intravenous Route: steady Dose: 228 mg, 2 times / day Sources: |
unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: |
Other AEs: Infusion site reactions, Gastrointestinal disorder (NOS)... Other AEs: Infusion site reactions (4.4%) Sources: Gastrointestinal disorder (NOS) (3%) Central nervous system disorder NOS (1.8%) |
10 mg/kg 2 times / day steady, intravenous Recommended Dose: 10 mg/kg, 2 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, preterm neonates Health Status: unhealthy Age Group: preterm neonates Sex: unknown Sources: |
Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5, 3 patients) Sources: |
500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, ≥18 years Health Status: unhealthy Age Group: ≥18 years Sex: F Sources: |
Disc. AE: Myalgia... AEs leading to discontinuation/dose reduction: Myalgia (2 patients) Sources: |
500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, ≥18 years Health Status: unhealthy Age Group: ≥18 years Sex: F Sources: |
Disc. AE: Exanthema... AEs leading to discontinuation/dose reduction: Exanthema (2 patients) Sources: |
500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Acute kidney injury, Clostridium difficile infection... Other AEs: Acute kidney injury (serious, 8 patients) Sources: Clostridium difficile infection (serious, 1 patient) Chest pain (serious, 1 patient) Dysuria (serious, 1 patient) Epistaxis (serious, 1 patient) GI bleed (serious, 1 patient) Hematuria (serious, 1 patient) Hyperkalemia (serious, 1 patient) Hypertension malignant (serious, 1 patient) Myocardial infarction (serious, 1 patient) Nausea (serious, 1 patient) Nephrolithiasis (serious, 1 patient) Neutropenia (serious, 1 patient) Pain (serious, 1 patient) Nephrostomy complication (serious, 1 patient) Radial nerve palsy (serious, 1 patient) Sepsis (serious, 2 patients) Small bowel obstruction (serious, 1 patient) Thrombocytopenia (serious, 1 patient) Urinary incontinence (serious, 1 patient) Urinary retention (serious, 3 patients) Vomiting (serious, 2 patients) Venous thromboembolism (serious, 5 patients) Wound complication (serious, 3 patients) Constipation (below serious, 12 patients) Headache (below serious, 7 patients) Hypomagnesemia (below serious, 8 patients) Insomnia (below serious, 8 patients) Osteopenia (below serious, 19 patients) Proteinuria (below serious, 12 patients) |
500 mg 2 times / day steady, oral Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy |
Other AEs: Diarrhea, Abdominal pain... Other AEs: Diarrhea (below serious, 2 patients) Sources: Abdominal pain (below serious, 2 patients) Headache (below serious, 2 patients) |
500 mg 2 times / day steady, oral Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy |
Other AEs: Rash... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Reaction gastrointestinal | 3% Disc. AE |
15 mg/kg 2 times / day steady, oral Recommended Dose: 15 mg/kg, 2 times / day Route: oral Route: steady Dose: 15 mg/kg, 2 times / day Sources: |
unhealthy, 1 - 17 years Health Status: unhealthy Age Group: 1 - 17 years Sex: unknown Sources: |
| Musculoskeletal disorder NOS | 9.3% | 15 mg/kg 2 times / day steady, oral Recommended Dose: 15 mg/kg, 2 times / day Route: oral Route: steady Dose: 15 mg/kg, 2 times / day Sources: |
unhealthy, 1 - 17 years Health Status: unhealthy Age Group: 1 - 17 years Sex: unknown Sources: |
| Renal tubular necrosis acute | 1 patient Disc. AE |
7.5 g single, oral Overdose |
unhealthy, 15 years |
| Pain epigastric | 1 patient Disc. AE |
12 g single, oral Overdose |
healthy, 16 years |
| Vomited | 58% | 20 mg/kg single, oral Recommended Dose: 20 mg/kg Route: oral Route: single Dose: 20 mg/kg Sources: |
unhealthy, 2-15 years Health Status: unhealthy Age Group: 2-15 years Sex: M+F Sources: |
| Acute renal failure | 1 patient Disc. AE |
28 g single, oral Overdose |
healthy, 29 years |
| Acute renal failure | 2 patients Disc. AE |
750 mg 2 times / day steady, oral Highest studied dose Dose: 750 mg, 2 times / day Route: oral Route: steady Dose: 750 mg, 2 times / day Sources: |
unhealthy, > 70 years Health Status: unhealthy Age Group: > 70 years Sex: M+F Sources: |
| Nausea and vomiting | 2 patients Disc. AE |
3 g single, oral Overdose |
healthy, adult |
| Central nervous system disorder NOS | 1.8% | 228 mg 2 times / day steady, intravenous Recommended Dose: 228 mg, 2 times / day Route: intravenous Route: steady Dose: 228 mg, 2 times / day Sources: |
unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: |
| Gastrointestinal disorder (NOS) | 3% | 228 mg 2 times / day steady, intravenous Recommended Dose: 228 mg, 2 times / day Route: intravenous Route: steady Dose: 228 mg, 2 times / day Sources: |
unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: |
| Infusion site reactions | 4.4% | 228 mg 2 times / day steady, intravenous Recommended Dose: 228 mg, 2 times / day Route: intravenous Route: steady Dose: 228 mg, 2 times / day Sources: |
unhealthy, mean 50 years Health Status: unhealthy Age Group: mean 50 years Sex: M+F Sources: |
| Death | grade 5, 3 patients Disc. AE |
10 mg/kg 2 times / day steady, intravenous Recommended Dose: 10 mg/kg, 2 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 2 times / day Sources: |
unhealthy, preterm neonates Health Status: unhealthy Age Group: preterm neonates Sex: unknown Sources: |
| Myalgia | 2 patients Disc. AE |
500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, ≥18 years Health Status: unhealthy Age Group: ≥18 years Sex: F Sources: |
| Exanthema | 2 patients Disc. AE |
500 mg 2 times / day steady, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy, ≥18 years Health Status: unhealthy Age Group: ≥18 years Sex: F Sources: |
| Constipation | below serious, 12 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Proteinuria | below serious, 12 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Osteopenia | below serious, 19 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Headache | below serious, 7 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Hypomagnesemia | below serious, 8 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Insomnia | below serious, 8 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Chest pain | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Clostridium difficile infection | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Dysuria | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Epistaxis | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| GI bleed | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Hematuria | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Hyperkalemia | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Hypertension malignant | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Myocardial infarction | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Nausea | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Nephrolithiasis | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Nephrostomy complication | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Neutropenia | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Pain | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Radial nerve palsy | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Small bowel obstruction | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Thrombocytopenia | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Urinary incontinence | serious, 1 patient | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Sepsis | serious, 2 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Vomiting | serious, 2 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Urinary retention | serious, 3 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Wound complication | serious, 3 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Venous thromboembolism | serious, 5 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Acute kidney injury | serious, 8 patients | 500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: |
unhealthy |
| Abdominal pain | below serious, 2 patients | 500 mg 2 times / day steady, oral Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy |
| Diarrhea | below serious, 2 patients | 500 mg 2 times / day steady, oral Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy |
| Headache | below serious, 2 patients | 500 mg 2 times / day steady, oral Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy |
| Rash | below serious, 1 patient | 500 mg 2 times / day steady, oral Dose: 500 mg, 2 times / day Route: oral Route: steady Dose: 500 mg, 2 times / day Sources: |
unhealthy |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [Activation 10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Activation 12.5893 uM] | ||||
| yes [Activation 15.84893 uM] | yes (co-administration study) Comment: Coadministration of Ciprofloxacin increased average Clozapine (CYP1A2 substrate) concentration by approximately 30% and Theophylline blood concentration and average half-life by about 20 to 30%.. |
|||
| yes [IC50 >10 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| yes | ||||
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Alterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatis. | 1999 Aug |
|
| The 2-pyridone antibacterial agents: 8-position modifications. | 1999 Jul |
|
| Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. | 1999 Jun |
|
| Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum. | 1999 Sep |
|
| Activity of moxifloxacin against mycobacteria. | 1999 Sep |
|
| Methadone, ciprofloxacin, and adverse drug reactions. | 2000 Dec 16 |
|
| Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. | 2000 May |
|
| Ciprofloxacin affects pregnancy loss in CBA/JxDBA/2J mice possibly via elevation of interleukin-3 and granulocyte macrophage-colony stimulating factor production. | 2000 Nov |
|
| Effect of ciprofloxacin on the activation of the transcription factors nuclear factor kappaB, activator protein-1 and nuclear factor-interleukin-6, and interleukin-6 and interleukin-8 mRNA expression in a human endothelial cell line. | 2000 Nov |
|
| The role of fluoroquinolones in tuberculosis today. | 2001 |
|
| Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. | 2001 Feb |
|
| Effect of pre-stain viability on the acid-fast staining characteristics of Mycobacterium species. | 2001 Feb |
|
| Would you get your Gonorrhoea treated in the north of England? | 2001 Feb |
|
| Neisseria gonorrhoeae resistant to ciprofloxacin: first report in Cuba. | 2001 Feb |
|
| Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. | 2001 Feb |
|
| Treatment of cat-scratch disease. | 2001 Feb |
|
| Emergence of high level ciprofloxacin resistant Neisseria gonorrhoeae strain in Buenos Aires, Argentina. | 2001 Feb |
|
| In vitro activity of new quinolones against Clostridium difficile. | 2001 Feb |
|
| Antibiotic susceptibility of Kingella kingae isolates from respiratory carriers and patients with invasive infections. | 2001 Feb |
|
| Evaluation of the Mastalex latex agglutination test for methicillin resistance in Staphylococcus aureus grown on different screening media. | 2001 Feb |
|
| Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia. | 2001 Jan |
|
| Comamonas acidovorans keratitis in a hydrogel contact lens wearer. | 2001 Jan |
|
| Microbiological profile of a shipboard environment and the flora on contact lenses of seamen. | 2001 Jan |
|
| Antimicrobial use and susceptibility rates in isolates from intensive care unit and other nosocomial inpatient and outpatient areas. | 2001 Jan |
|
| Determination by fluorimetric titration of the ionization constants of ciprofloxacin in solution and in the presence of liposomes. | 2001 Jan |
|
| Nosocomial pneumonia. Diagnostic and therapeutic considerations. | 2001 Jan |
|
| Insect wing case: unusual foreign body. | 2001 Jan |
|
| Efficacy of ofloxacin and other otic preparations for otitis externa. | 2001 Jan |
|
| Compliance issues related to the selection of antibiotic suspensions for children. | 2001 Jan |
|
| Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. | 2001 Jan |
|
| Comparison of serum bactericidal activity of ceftazidime, ciprofloxacin and meropenem against Stenotrophomonas maltophilia. | 2001 Jan |
|
| In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. | 2001 Jan |
|
| Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. | 2001 Jan |
|
| [Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. | 2001 Jan 13 |
|
| Pediatric travel consultation in an integrated clinic. | 2001 Jan-Feb |
|
| Radical meatoplasty in the treatment of severe chronic external otitis. | 2001 Jan-Feb |
|
| Depression or hypoactive delirium? A report of ciprofloxacin-induced mental disorder in a patient with chronic obstructive pulmonary disease. | 2001 Jan-Feb |
|
| In vitro development of resistance to three quinolones in Streptococcus pneumoniae. | 2001 Jan-Feb |
|
| Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. | 2001 Mar |
|
| Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. | 2001 Mar |
|
| A case of rhinoscleroma treated with ciprofloxacin. | 2001 Mar |
|
| Chryseobacterium in burn wounds. | 2001 Mar |
|
| Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
| Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. | 2001 Mar |
|
| Ciprofloxacin resistance in gonococci. | 2001 Mar 10 |
|
| What have we learned from pharmacokinetic and pharmacodynamic theories? | 2001 Mar 15 |
|
| Successful treatment of an infant with Chromobacterium violaceum sepsis. | 2001 Mar 15 |
|
| Treatment failure with the use of ciprofloxacin for gonorrhea correlates with the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae strains in Bangladesh. | 2001 Mar 15 |
|
| In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany. | 2001 Mar-Apr |
|
| Association between antibiotic resistance and the expression of Dr adhesin among uropathogenic Escherichia coli. | 2001 Mar-Apr |
Sample Use Guides
Skin and Skin Structure 500 -750 mg every 12 hours 7 to 14 days
Bone and Joint 500-750 mg every 12 hours 4 to 8 weeks
Complicated Intra-Abdominal 500 mg every 12 hours 7 to 14 days
Infectious Diarrhea 500 mg every 12 hours 5 to 7 days
Typhoid Fever 500 mg every 12 hours 10 days
Uncomplicated Gonorrhea 250 mg single dose single dose
Inhalational anthrax (pos-exposure) 500 mg every 12 hours 60 days
Plague 500–750 mg every 12 hours 14 days
Chronic Bacterial Prostatitis 500 mg every 12 hours 28 days
Lower Respiratory Tract 500 -750 mg every 12 hours 7 to 14 days
Urinary Tract 250-500 mg every 12 hours 7 to 14 days
Acute Uncomplicated Cystitis 250 mg every 12 hours 3 days
Acute Sinusitis 500 mg every 12 hours 10 days
Route of Administration:
Oral
Eight hospital isolates of methicillin-resistant and two standard strains of S. epidermidis (ATCC 12228, ATCC 35984) were cultured overnight in Tryptone Soy Broth supplemented with 0.5% glucose. The solution of tested compounds in TSB-glucose medium were mixed (1:1) with the bacterial inoculums (10^7 CFU/mL) in sterile 96-well polystyrene microtiter plates (Karell - Medlab, Italy) and incubated at 37 C for 24 h. Ciprofloxacin was used as the reference antimicrobial compound; its final concentration ranged from 0.125 to 8 mkg/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:10:01 GMT 2025
by
admin
on
Mon Mar 31 21:10:01 GMT 2025
|
| Record UNII |
G43NV09DD4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76961290
Created by
admin on Mon Mar 31 21:10:01 GMT 2025 , Edited by admin on Mon Mar 31 21:10:01 GMT 2025
|
PRIMARY | |||
|
G43NV09DD4
Created by
admin on Mon Mar 31 21:10:01 GMT 2025 , Edited by admin on Mon Mar 31 21:10:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |